𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation

✍ Scribed by Figg, William D.; Hussain, Maha H.; Gulley, James L.; Arlen, Philip M.; Aragon-Ching, Jeanny B.; Petrylak, Daniel P.; Higano, Celestia S.; Steinberg, Seth M.; Chatta, Gurkamal S.; Parnes, Howard; Wright, John J.; Sartor, Oliver; Dahut, William L.

Book ID
123358417
Publisher
Lippincott Williams and Wilkins
Year
2009
Tongue
English
Weight
407 KB
Volume
181
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Commentary on A double-blind randomized
Commentary on A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation: Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
✍ Donald L. Trump πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 94 KB
The antiosteoporotic efficacy of intrave
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade : A double blind, randomized, placebo-controlled crossover study
✍ Terrence H. Diamond; Julie Winters; Angie Smith; Paul De Souza; John H. Kersley; πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

## BACKGROUND. Prostate carcinoma therapy with combined androgen blockade may result in high bone-turnover with significant bone loss. This study was undertaken to evaluate the antiosteoporotic efficacy of intravenous pamidronate in a double blind, randomized, placebo-controlled, crossover study.

Intermittent chemotherapy in patients wi
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th